What ChondroFiller typically costs

Guide costs for ChondroFiller injection in the UK run from £3,000 to £8,000, structured around how much collagen scaffold the defect requires.

| Defect size | Boxes needed | Guide cost | |---|---|---| | Up to ~3 cm² | 1 box | £3,000 | | Up to ~4.5 cm² | 2 boxes | £5,500 | | Up to ~6 cm² | 3 boxes | £8,000 |

Complex or multi-compartment presentations may attract a guide figure of approximately £9,800.

For most patients, the single-box figure is the most practically relevant starting point. The majority of people presenting with a single focal cartilage defect are treated with one box, placing the typical cost at £3,000. Defect surface area cannot be confirmed reliably without imaging review, so the tier that applies to any individual patient only becomes clear after a scan has been assessed by a consultant.

Published tariffs are currently most visible from London Cartilage Clinic, the first UK clinic to offer ChondroFiller as an injection. Comparable pricing from other UK providers is less widely published, so it is worth confirming costs directly with the treating clinic before proceeding. All figures should be read as guide costs rather than fixed quotes.

What the package price covers

Why does a ChondroFiller injection cost substantially more than a hyaluronic acid or corticosteroid injection? The answer lies in regulatory classification, not clinic economics.

ChondroFiller is a CE-marked Class III medical device — the highest-risk category in European medical device regulation, equivalent to implantable cardiac monitors or orthopaedic joint components. Standard injectables such as hyaluronic acid and corticosteroids are pharmaceutical products that travel a different, lower-cost regulatory and supply pathway. ChondroFiller, by contrast, is imported to the UK under prescription by its German manufacturer, Meidrix Biomedicals GmbH, and the unit cost of the implant itself represents the largest single component of the overall price. That cost is intrinsic to the product's classification — not primarily a clinic margin.

Published UK tariffs are structured as all-inclusive packages, so the figure quoted is a complete cost — there are no separately itemised fees for consultation, imaging, or follow-up on top. If comparing quotes across providers, any itemised or headline figure that appears lower should be checked carefully: elements routinely included in a package price elsewhere may be billed separately, bringing the true total closer to the guide range than the headline suggests.

NHS access: the current position

ChondroFiller is not currently available on the NHS, and GPs have no referral route into this pathway on the public system.

ChondroFiller holds no NICE health technology appraisal and sits outside all NHS commissioning frameworks. The only cartilage cell therapy the NHS currently commissions is autologous chondrocyte implantation (ACI), which received approval in 2017. ACI is a different intervention — a staged surgical procedure requiring cartilage cell harvesting and reimplantation under general anaesthetic — and is not interchangeable with ChondroFiller's injection pathway.

Individual Funding Requests (IFRs) theoretically allow NHS trusts to fund treatments outside standard commissioning on exceptional-circumstances grounds. In practice, no published precedent confirms a successful IFR for ChondroFiller, and patients should not plan on this route as a realistic option.

ChondroFiller is therefore a privately funded treatment. For patients who have reached this point in their decision-making, understanding the guide-cost structure and whether private insurance may contribute are the two most practical next questions.

Private insurance: what to check before booking

Before booking, it is worth spending time on the phone with your insurer — coverage exists but is far from automatic.

Some UK private medical insurers have approved claims for ChondroFiller. Bupa, Aviva, and WPA are the names most commonly cited in UK practice as having done so. That said, each case is assessed individually against the patient's policy terms and clinical documentation, so approval with one insurer on one policy does not predict approval elsewhere. Partial coverage — where the insurer meets a portion but not the full cost — is a common outcome, and patients should budget on the assumption that some out-of-pocket contribution may remain regardless of insurer approval.

In the wider UK market, ChondroFiller-related procedures have been mapped to CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500; these codes appear on the fee schedules of several UK insurers. This is offered as market context rather than a guarantee that any specific clinic's billing will be accepted on those terms.

Written pre-authorisation before the date of treatment is non-negotiable. Retrospective claims — submitted after the procedure has already taken place — are rarely successful. Once a treating consultant considers ChondroFiller clinically appropriate, contacting your insurer at that point, with supporting clinical documentation from the treating clinic, is the correct sequence. Do not book until authorisation is confirmed in writing.

Finally, insurer policies change. The landscape described here reflects guidance current to late 2025; verify your own policy's terms directly with your insurer before proceeding.

The treatment appointment and recovery

On the day of treatment, the appointment itself is straightforward by the standards of any cartilage intervention. ChondroFiller is placed under real-time ultrasound guidance as an outpatient procedure lasting approximately 30–45 minutes. No theatre admission, no general anaesthetic — local anaesthetic or mild sedation is used, and patients go home the same day.

The mechanism at work once the scaffold is in place is acellular matrix-induced chondrogenesis: the injected collagen gel recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone to support endogenous repair. This is distinct from cartilage regrowth in the surgical sense; full scaffold integration with mature tissue takes one to two years.

Recovery scales considerably with the joint treated. Small joint injections — elbow or wrist, for example — typically require around one to two weeks of rest before normal activity resumes. For the knee, the return-to-sport pathway is phased over 6–12 months, with progressive loading introduced from around week six onwards.

Published outcome data for knee cases shows approximately 30-point improvement in IKDC scores at 12 months, a major complication rate of approximately zero per cent, and a reoperation rate in the range of 3–8% — comparing favourably with microfracture, where reoperation rates in some series reach 41%, and with ACI or MACI, where complication rates can reach 17%.

There is no published upper age limit for the injection route, and no fixed defect-size exclusion. Suitability is determined by imaging review and clinical assessment at the point of consultation.

Getting an accurate quote at MSK Doctors

Confirmed pricing depends on imaging. The guide tiers above assume certain defect dimensions, but the actual surface area — and therefore the number of boxes required — can only be established once MRI or comparable imaging of the joint has been reviewed by a treating clinician.

For patients who do not yet have recent imaging, the MSK Doctors site in Sleaford carries an on-site Open MRI scanner, which removes the need to arrange a separate scan before a consultation can proceed.

A first appointment requires no GP referral and no NHS waiting list. At consultation, the clinical team reviews imaging and history, confirms which price tier applies, and assesses whether ChondroFiller is the most appropriate option for the defect pattern in question — there is no obligation to proceed on the day.

London-based patients are typically seen through London Cartilage Clinic, the group's London arm, which offers the same injectable scaffold pathway.

To arrange a consultation without referral, visit mskdoctors.com.